Biological therapy update in colorectal cancer

Bibliography

• BERGERS G, BENJAMIN LE: Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer (2003) 3(6):401-410.
   PubMed Web of Science ®Google Scholar
• HATTORI K, DIAS S, HEISSIG B et al.: Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. (2001) 193(9):1005-1014.
   PubMed Web of Science ®Google Scholar
• HATTORI K, HEISSIG B, WU Y et al.: Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment. Nat. Med. (2002) 8(8):841-849.
   PubMed Web of Science ®Google Scholar
• FERRARA N: VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer (2002) 2(10):795-803.
   PubMed Web of Science ®Google Scholar
• DOR Y, PORAT R, KESHET E: Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol. Cell Physiol. (2001) 280(6):C1367-C1374.
   PubMed Web of Science ®Google Scholar
• ROBERTS W, PALADE G: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. (1995) 108(6):2369-2379.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. (2001) 7(9):987-989.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Barriers to drug delivery in solid tumors. Sci. Am. (1994) 271:58-65.
   PubMed Web of Science ®Google Scholar
• FERRARA N, HILLAN KJ, GERBER HP, NOVOTNY W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. (2004) 3(5):391-400.
   PubMed Web of Science ®Google Scholar
• LEE J, CHOW N, WANG S, HUANG S: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer (2000) 36(6):748-753.
   PubMed Web of Science ®Google Scholar
• CHOI HJ, HYUN MS, JUNG GJ, KIM SS, HONG SH: Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology (1998) 55(6):575-581.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI Y, KITADAI Y, BUCANA C, CLEARY K, ELLIS L: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. (1995) 55(18):3964-3968.
   PubMed Web of Science ®Google Scholar
• WILLETT CG, BOUCHER Y, DI TOMASO E et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. (2004) 10(2):145-147.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342.
   PubMed Web of Science ®Google Scholar
• GIANTONIO BJ, CATALANO PJ, MEROPOL NJ: The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an updated interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, USA (22 – 24 January 2004).
   Google Scholar
• REDDY GK: The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial. Clin. Colorectal Cancer (2005) 4(5):300-301.
   PubMedGoogle Scholar
• GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study 3200. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Hollywood, FL, USA (27 – 29 January 2005).
   Google Scholar
• GIANTONIO BJ, CATALANO PJ, O’DWYER PJ, MEROPOL NJ, BENSON AB III: Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group’s Study E3200. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, USA (26 – 28 January 2006).
   Google Scholar
• EMMANOUILIDES C, PEGRAM M, ROBINSON R et al.: Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech. Coloproctol. (2004) 8:s50-s52.
   PubMedGoogle Scholar
• SALTZ LB, LENZ H-J, HOCHSTER H et al.: Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA (13 – 17 May 2005).
   Google Scholar
• FUCHS C, MARSHALL J, MITCHELL E et al.: A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2 – 6 June 2006).
   Google Scholar
• HOCHSTER HS, HART LL, RAMANATHAN RK et al.: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2 – 6 June 2006).
   Google Scholar
• CASSIDY J, CLARKE S, RUBIO ED et al.: First efficacy and safety results from XELOX-1/NO16968, a randomized 2x2 factorial Phase III trial of XELOX versus FOLFOX4+ bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Abstract Book of the 31st ESMO Congress. Istanbul, Turkey (29 September – 3 October 2006).
   Google Scholar
• BERRY SR, CUNNINGHAM D, MICHAEL M et al.: Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC-First B.E.A.Trial. American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2 – 6 June 2006).
   Google Scholar
• HEDRICK E, KOZLOFF M, HAINSWORTH J et al.: Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2 – 6 June 2006).
   Google Scholar
• SALTZ LB, CHUNG KY, TIMONEY J, PARK V, HOLLYWOOD E: Simplification of bevacizumab (bev) administration: do we need 90, 60, or even 30 minute infusion times? American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2 – 6 June 2006).
   Google Scholar
• TAKAHASHI Y, TUCKER SL, KITADAI Y et al.: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg. (1997) 132(5):541-546.
   PubMed Web of Science ®Google Scholar
• ISHIGAMI SI, ARII S, FURUTANI M et al.: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer (1998) 78(10):1379-1384.
   PubMed Web of Science ®Google Scholar
• WARREN RS, YUAN H, MATLI MR, GILLETT NA, FERRARA N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. (1995) 95(4):1789-1797.
   PubMed Web of Science ®Google Scholar
• AMAYA H, TANIGAWA N, LU C et al.: Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett. (1997) 119(2):227-235.
   PubMed Web of Science ®Google Scholar
• DIAZ-RUBIO E, SCHMOLL HJ: The future development of bevacizumab in colorectal cancer. Oncology (Huntington) (2005) 69(Suppl. 3):34-45.
   Google Scholar
• STEWARD WP, THOMAS A, MORGAN B et al.: Expanded Phase I/II study of PTK787/ZK 222584(PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA (5 – 8 June 2004).
   Google Scholar
• SCHLEUCHER N, TRARBACH T, JUNKER U et al.: Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA (5 – 8 June 2004).
   Google Scholar
• THOMAS A, MORGAN B, DREVS J et al.: Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 Phase I studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. American Society of Clinical Oncology Annual Meeting. San Francisco, CA, USA (12 – 15 May 2001).
   Google Scholar
• HECHT JR, TRARBACH T, JAEGER E et al.: A randomized, double-blind, placebo-controlled, Phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA (13 – 17 May 2005).
   Google Scholar
• TYAGI P: Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin. Colorectal Cancer (2005) 5(1):24-26.
   PubMedGoogle Scholar
• KOEHNE C, BAJETTA E, LIN E et al.: Results of an interim analysis of a multinational randomized, double-blind, Phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584(PTK/ZK) or placebo (CONFIRM 2). American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2 – 6 June 2006).
   Google Scholar
• MAINDRAULT-GOEBEL F, LLEDO G, CHIBAUDEL B et al.: OPTIMOX2, a large randomized Phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2 – 6 June 2006).
   Google Scholar
• BASELGA J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist (2002) 7:2-8.
   PubMed Web of Science ®Google Scholar
• BASELGA J, ALBANELL J: Epithelial growth factor receptor interacting agents. Hematol. Oncol. Clin. North Am. (2002) 16(5):1041-1063.
   PubMed Web of Science ®Google Scholar
• SALOMON DS, BRANDT R, CIARDIELLO F, NORMANNO N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. (1995) 19(3):183-232.
   PubMed Web of Science ®Google Scholar
• MAYER A, TAKIMOTO M, FRITZ E et al.: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 71(8):2454-2460.
   PubMed Web of Science ®Google Scholar
• SATO JD, KAWAMOTO T, LE AD et al.: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. (1983) 1:511-529.
   PubMedGoogle Scholar
• MENDELSOHN J, BASELGA J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. (2003) 21(14):2787-2799.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351(4):337-345.
   PubMed Web of Science ®Google Scholar
• ALEKSHUN T, GARRETT C: Targeted therapies in the treatment of colorectal cancers. Cancer Control (2005) 12(2):105-110.
   PubMedGoogle Scholar
• SALTZ LB, RUBIN M, HOCHSTER HS et al.: Acne-like rash predicts response in patients treated with cetuximab (IMC-225) plus irinotecan (CPT-11) in CPT-11 refractory colorectal cancer that expresses EGFR. J. Clin. Invest. (2001) 68:559.
   Google Scholar
• SALTZ LB, RUBIN M, HOCHSTER HS et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). American Society of Clinical Oncology Annual Meeting. San Francisco, CA, USA (12 – 15 May 2001).
   Google Scholar
• VENOOK A, NIEDZWIECKI D, HOLLIS D et al.: Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) {+/-} cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2 – 6 June 2006).
   Google Scholar
• VINCENZI B, SANTINI D, RABITTI C et al.: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre Phase II trial. Br. J. Cancer (2006) 94(6):792-797.
   PubMed Web of Science ®Google Scholar
• SOBRERO A, SCHEITHAUER W, MAUREL J et al.: Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of the first 400 patients in a randomized Phase III trial (EPIC). American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA (13 – 17 May 2005).
   Google Scholar
• ROUGIER P, RAOUL J-L, VAN LAETHEM J-L et al.: Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA (5 – 8 June 2004).
   Google Scholar
• BALIN-GAUTHIER D, DELORD JP, ROCHAIX P et al.: In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother. Pharmacol. (2006) 57(6):709-718.
   PubMed Web of Science ®Google Scholar
• BADARINATH S, MITCHELL EP, JENNIS A et al.: Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized Phase III trial. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA (5 – 8 June 2004).
   Google Scholar
• CHUNG KY, SHIA J, KEMENY NE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. (2005) 23(9):1803-1810.
   PubMed Web of Science ®Google Scholar
• TONRA JR, DEEVI DS, CORCORAN E et al.: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. (2006) 12(7):2197-2207.
   PubMed Web of Science ®Google Scholar
• HERBST RS, JOHNSON DH, MININBERG E et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. (2005) 23(11):2544-2555.
   PubMed Web of Science ®Google Scholar
• HERBST RS, MININBERG E, HENDERSON T et al.: Phase I/II trial evaluating blockade of tumour blood suppl.y and tumour cell proleferation with combined bevacizumab and erlotinib hci as targeted cancer therapy in patients with recurrent non-small cell lung cancer. Eur. J. Cancer (2003) 1(5):s293.
   Google Scholar
• SELVAGGI G, NOVELLO S, TORRI V et al.: Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann. Oncol. (2004) 15(1):28-32.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, BIANCO R, DAMIANO V et al.: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. (2000) 6(9):3739-3747.
   PubMed Web of Science ®Google Scholar
• SHAHEEN RM, AHMAD SA, LIU W et al.: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br. J. Cancer (2001) 85(4):584-589.
   PubMed Web of Science ®Google Scholar
• MACKENZIE MJ, HIRTE HW, GLENWOOD G et al.: A Phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest. New Drugs (2005) 23(2):165-170.
   Google Scholar
• CHO CD, FISHER GA, HALSEY J, SIKIC BI: Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Invest. New Drugs (2006) 24(2):117-123.
   Google Scholar
• FOON KA, YANG X-D, WEINER LM et al.: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(3):984-990.
   PubMed Web of Science ®Google Scholar
• PEETERS M, VAN CUTSEM E, SALVATORE S et al.: A Phase III, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) versus BSC in patients (pts) with metastatic colorectal cancer (mCRC). Proceedings, Annual Meeting of the American Association for Cancer Research. Washington DC, USA (1 – 5 April 2006).
   Google Scholar
• WAINBERG Z, HECHT JR: A Phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin. Colorectal Cancer (2006) 5(5):363-367.
   PubMed Web of Science ®Google Scholar
• HECHT JR, PATNAIK A, MALIK I et al.: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA (5 – 8 June 2004).
   Google Scholar
• BERLIN J, NEUBAUER M, SWANSON P et al.: Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing > = 10% epidermal growth factor receptor (EGFr). American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2 – 6 June 2006).
   Google Scholar
• WILD R, FAGER K, FLEFLEH C et al.: Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol. Cancer Ther. (2006) 5(1):104-113.
   Google Scholar
• VALLBOHMER D, ZHANG W, GORDON M et al.: Molecular determinants of cetuximab efficacy. J. Clin. Oncol. (2005) 23(15):3536-3544.
   PubMed Web of Science ®Google Scholar
• MORONI M, VERONESE S, BENVENUTI S et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. (2005) 6(5):279-286.
   PubMed Web of Science ®Google Scholar
• JUBB AM, HURWITZ HI, BAI W et al.: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. (2006) 24(2):217-227.
   PubMed Web of Science ®Google Scholar
• INCE WL, JUBB AM, HOLDEN SN et al.: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl Cancer Inst. (2005) 97(13):981-989.
   PubMed Web of Science ®Google Scholar
• ULLENHAG GJ, SPENDLOVE I, WATSON NF et al.: A Neoadjuvant/ adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin. Cancer Res. (2006) 12(24):7389-7396.
   PubMed Web of Science ®Google Scholar